(Q37436365)

20 August 2017

1 reference

title

Successful translation of pharmacogenetics into the clinic: the abacavir example (English)

1 reference

20 August 2017

1 reference

Elizabeth J. Phillips

series ordinal

1

object named as

Elizabeth Phillips

1 reference

20 August 2017

2

Simon Mallal

1 reference

20 August 2017

language of work or name

1 reference

1 January 2009

1 reference

Molecular Diagnosis and Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

13

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

1-9

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256308

20 August 2017

exact match

0 references

cites work

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Drug hypersensitivity in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

The abacavir hypersensitivity reaction: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Hypersensitivity related to abacavir in two members of a family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Risk factor analysis of hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Pharmacogenetics and the potential for the individualization of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Clinical and immunogenetic correlates of abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

A review of drug patch testing and implications for HIV clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

Abacavir Hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256308

External quality assessment of HLA-B*5701 reporting: an international multicentre survey

21 January 2018

1 reference

12 December 2020

HLA-Cw8 primarily associated with hypersensitivity to nevirapine

1 reference

12 December 2020

Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?

1 reference

12 December 2020

A near-fatal hypersensitivity reaction to abacavir: case report and literature review

1 reference

12 December 2020

A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome

1 reference

12 December 2020

Cytokine profiling in abacavir hypersensitivity patients.

1 reference

12 December 2020

A marker for Stevens-Johnson syndrome ...: ethnicity matters

1 reference

12 December 2020

HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay

1 reference

12 December 2020

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256308

1 reference

20 August 2017

1 reference